An integrated workflow for proteome-wide off-target identification and polypharmacology drug design

Proceedings - 2012 IEEE International Conference on Bioinformatics and Biomedicine Workshops, BIBMW 2012

Volumn , Issue , 2012, Pages 32-39

  Evangelidis, Thomas ^a   Bourne, Philip E ^b   Xie, Li ^b   Xie, Lei ^c  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Drug discovery; off target; polypharmacology; structural proteomics; systems biology

Indexed keywords

DRUG DISCOVERY; OFF-TARGET; POLYPHARMACOLOGY; PROTEOMICS; SYSTEMS BIOLOGY;

BINDING SITES; MOLECULAR BIOLOGY;

BIOINFORMATICS;

EID: 84875600462     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/BIBMW.2012.6470348     Document Type: Conference Paper

References (53)

1. L. Xie, et al., "Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual Drugs,"Annu Rev Pharmacol Toxicol, vol. 52, pp. 361-379, Jan 17 2012.
2. E. L. Tobinick, "The value of drug repositioning in the current pharmaceutical market," Drug News Perspect, vol. 22, pp. 119-25, Mar 2009.
3. H. M. Berman, et al., "The Protein Data Bank," Nucleic Acids Res, vol. 28, pp. 235-42, Jan 1 2000.
4. D. S. Wishart, et al., "DrugBank: a knowledgebase for drugs, drug actions and drug targets," Nucleic Acids Res, vol. 36, pp. D901-6, Jan 2008.
5. B. Chen, et al., "PubChem as a source of polypharmacology," J Chem InfModel, vol. 49, pp. 2044-55, Sep 2009.
6. Y. Wang, et al., "PubChem: a public information system for analyzing bioactivities of small molecules," Nucleic Acids Res, vol. 37, pp. W62333, Jul1 2009.
7. A. Gaulton, et al., "ChEMBL: a large-scale bioactivity database for drug discovery," Nucleic Acids Res, vol. 40, pp. D1100-7, Jan 2012.
8. M. 1. Keiser, et al., "Relating protein pharmacology by ligand chemistry," Nat Biotechnol, vol. 25, pp. 197-206, Feb 2007.
9. M. J. Keiser, et al., "Predicting new molecular targets for known drugs," Nature, vol. 462, pp. 175-81, Nov 12 2009.
10. F. Iorio, et al., "Identifying network of drug mode of action by gene expression profiling," J Comput BioI, vol. 16, pp. 241-51, Feb 2009.
11. M. Campillos, et al., "Drug target identification using side-effect similarity," Science, vol. 321, pp. 263-6, Ju1112008.
12. L. Xie, et al., "Structure-based systems biology for analyzing off-target binding," Curr Opin Struct BioI, vol. 21, pp. 189-199, Feb 1 2011.
13. S. L. Kinnings, et al., "Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis," PLoS Comput Biol, vol. 5, p.e1000423,JuI2009.
14. S. 1.Ho Sui, et al., "Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence," Int J Antimicrob Agents, vol. 40, pp. 246-51, Sep 2012.
15. J.D. Durrant, et al., "A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology," PLoS Comput BioI, vol. 6, p. e1000648, 2010.
16. L. Xie, et al., "In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators," PLoS Comput Biol, vol. 3, p. e217, Nov 2007.
17. L. Xie, et al., "Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors," PLoS Comput BioI, vol. 5, p. e1000387, May 2009.
18. L. Xie, et al., "Drug Discovery Using Chemical Systems Biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of Nelfinavir.," PLoS Comp BioI, vol. 7, p. e1002037, 2011.
19. R. L. Chang, etal., "Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model," PLoS Comp Biol, vol. 6,p. e1000938, 2010.
20. S. L. Kinnings, et al., "The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications.," PLoS Comp Biol, vol. 6, p. e100976, 2010. 38
21. L. Xie and P. E. Bourne, "A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites," BMC Bioinformatics, vol. 8, p. S9, 2007.
22. L. Xie and P. E. Bourne, "Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments," Proc. Natl. Acad. Sci. USA, vol. 105, pp.5441-5446,2007.
23. N. A. Baker, etal., "Electrostatics ofnanosystems: application to microtubules and the ribosome.," Proc. Natl. Acad. Sci. USA, vol. 98, pp. 1003710041,2001.
24. L. Xie and P. E. Bourne, "Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments," Proc NatlAcad Sci U SA, vol. 105, pp. 5441-6, Apr 8 2008.
25. L. Xie and P. E. Bourne, "A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery," Bi0 inform atics, vol. 25, pp. i305-12, Jun 15 2009.
26. A. N. Jain, "Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search.," J. Comput. Aided Mol. Des., vol. 21, pp. 281-306,2007.
27. G. M. Morris, et al., "Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function," Journal of Computational Chemistry, vol. 19, pp. 1639-1662, Nov 15 1998.
28. O. Trott and A. 1. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading," J Comput Chem, vol. 31, pp. 45561, Jan 30 2009.
29. L. Xie and P. E. Bourne, "Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments," Proc. Natl. Acad. Sci. USA, vol. 105, pp. 5441-5446,2008.
30. L. Xie, et al., "A unified statistical model to support local sequence order independent similarity searching for ligand binding sites and its application to genome-based drug discovery," Bi0 inform atics, vol. 25, pp. i305-i312, 2009.
31. J. R. Miller, et al., "A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore," Proc NatlAcad Sci U SA, vol. 106, pp. 1737-1742, Feb 102009.
32. S. L. Kinnings, et al., "Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis," PLoS Comp Biol, vol. 5, p. el000423, Ju12009.
33. O. Guvench and A. D. Mackerell, Jr., "Computational evaluation of protein-small molecule binding, " Curr Opin Struct BioI, vol. 19, pp. 56-61, Feb 2009.
34. G. Carta, et al., "Unbiasing scoring functions: a new normalization and rescoring strategy," J ChernIn! Model, vol. 47, pp. 1564-71, Jul-Aug 2007.
35. B. K. Shoichet and J. J. Irwin, "ZINC-a free database of commercially available compounds for virtual screening.," J. Chern. In! Model., vol. 45, pp. 177182,2005.
36. A. Bairoch, et al., "The Universal Protein Resource (UniProt)," Nucleic Acids Res., vol. 33, pp. D154D159, 2005.
37. J. M. Fernandez, et al., "iHOP web services," Nucleic Acids Res, vol. 35, pp. W21-W26, Jul 07 2007.
38. A. Schlicker and M. Albrecht, "FunSimMat: a comprehensive functional similarity database," Nucleic Acids Res, vol. 36, pp. D434-D439, Jan 11 2008.
39. J. Gills, et al., "Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticu1um stress, autophagy, and apoptosis in vitro and in vivo," Clin Cancer Res, vol. 13, pp. 5183-5194,2007.
40. J. J. Gills, et al., "Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy," Autophagy, vol. 4, pp. 107-9, 2008.
41. N. Pore, et al., "HIV protease inhibitors decrease VEGF/HIF-lalpha expression and angiogenesis in glioblastoma cells," Neoplasia, vol. 8, pp. 889-895, 2006.
42. K. C. Cuneo, et al., "HIV protease inhibitors enhance the efficacy of irradiation," Cancer Res, vo1. 67, pp.4886-4893,2007.
43. J. P. Plastaras, et al., "Validation and Toxicity of P13K1Akt Pathway Inhibition by HIV Protease Inhibitors in Humans," Cancer Biol Ther, vol. 7, pp. 628-635, 2008.
44. J.D. Carpten, et al., "A transforming mutation in the pleckstrin homology domain of AKTI in cancer," Nature, vol. 448, pp. 439-444, 448.
45. Q. Meng, et al., "Role ofPI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6Kl pathway," Cell Signal, vol. 18, pp. 2262-2271, 2006.
46. X. Ju, et al., "Aktl governs breast cancer progression in vivo," Proc NatlAcad Sci U SA, vol. 104, pp. 7738-7743, 2007.
47. Z. Q. Yuan, et al., "Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-0H kinase/Akt pathway in human ovarian cancer.," Oncogene, vol. 19, pp. 2324-2330, 2000. 39
48. A. Faridmoayer, et al., "Extreme substrate promiscuity of the Neisseria oligosaccharyl transferase involved in protein O-glycosylation," J Biol Chern, vol. 283, pp. 34596-604, Dec 12 2008.
49. S. Tanno, et al., "AKT activation up-regulates insu1inlike growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells," Cancer Res, vol. 61, pp. 589-593,2001.
50. X. H. Shi, et al., "Combined silencing ofK-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo," Cancer Gene Therapy, vol. in print, 2008.
51. EntrezGene. Summary for AKT3 [Online]. Available: http://www.ncbi.nlm. nih.gov/sites/entrez?db=gene &cmd=Retrieve&dopt=full report&list uids=1000 Q
52. L. Castagnoli, et al., "Selectivity and promiscuity in the interaction network mediated by protein recognition modules," FEBS Lett, vol. 567, pp. 749, Jun 1 2004.
53. A. K. Gupta, et al., "HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo," Cancer Res, vol. 65, pp. 82568265,2005.